Lorem ipsum dolor sit amet, consectetur adipiscing elit. Suspendisse varius enim in eros elementum tristique. Duis cursus, mi quis viverra ornare, eros dolor interdum nulla, ut commodo diam libero vitae erat. Aenean faucibus nibh et justo cursus id rutrum lorem imperdiet. Nunc ut sem vitae risus tristique posuere.

This is some text inside of a div block.
This is some text inside of a div block.

Problem Tech Solves

Tech Brief

Biofourmis’ Care-at-Home technology provides healthcare delivery organizations with a comprehensive technology-enabled remote patient monitoring solution that spans the continuum of care, including acute (hospital-at-home), post-discharge care, and chronic disease management. Biofourmis’ technology-enabled end-to-end solution includes clinician- and patient-facing technology, materials and supplies sourcing, operational services, logistics and technical support, compliance, monitoring and a skilled and experienced multidisciplinary care team with registered nurses and physicians who monitor the patient around the clock (or organizations can provide their own). Biofourmis Care-at-Home offers more than remote patient monitoring—the solution elevates the care delivery method to remote patient “management.” Biofourmis' solution has many applications that are improving clinical care for those who need it most. For example, Appalachian Regional Health system in Kentucky and Blessing Health System in Illinois are both leveraging Biofourmis' solution to enable them to participate in the Rural Home Hospital project, a joint venture of the Harvard T.J. Chan School of Public Health and Brigham and Women’s Hospital in Massachusetts. The two health systems are the only U.S. participants selected for the program, which delivers acute hospital-level care inside patients’ homes and includes a clinical trial studying this care model in rural areas. In addition, Biofourmis' solution has been selected by the American College of Cardiology (ACC) for its TRANSFORM3 study that evaluates different intervention strategies for improving adherence to guideline-directed medication therapy (GDMT) for managing chronic cardiovascular conditions. The study places an emphasis on underserved populations and those with a history of healthcare disparities.

Tech Differentiators

Biofourmis Care-at-Home is the industry’s only truly comprehensive, end-to-end, turnkey, technology-enabled remote management service that includes an AI-based, clinically validated platform, compatibility with dozens of FDA-approved medical-grade wearable biosensors, a patient app, clinician dashboard, and a skilled and experienced multidisciplinary care team—all seamlessly integrated with solutions such as telehealth and video conferencing. Competitors may offer one or more of these components but not the full solution. While comprehensive in its design, Biofourmis Care-at-Home is also a modular build so it can be easily and quickly adapted and customized for various disease states and applications. Through its AI-powered and FDA-cleared analytics engine, Biovitals, Biofourmis offers continuous surveillance for a precise, real-time snapshot of a patient’s condition and personalized patterns over time. Many competitors monitor patients only at intervals every few hours, which does not provide a full view of their health and can increase the time it takes to flag decompensation requiring a medical intervention. Biofourmis Care-at-Home includes both active and passive data collection, while other solutions rely on patients/family caregivers to supply data via periodic monitoring with Bluetooth devices or even manual entry of basic data into an app. Biofourmis can collect more than 20 physiological parameters that continuously feed the AI-based analytics engine to notify clinicians of any decompensation early on, so that the clinician can intervene and prevent a medical crisis.


The most notable research demonstrating Biofourmis Care’s positive ROI is an Annals of Internal Medicine randomized controlled trial (https://www.acpjournals.org/doi/abs/10.7326/M19-0600) conducted by Brigham and Women’s Hospital in Boston. Biofourmis’ solution has played a pivotal role in Brigham’s home hospital program. In the study, which included nearly 100 patients, home-based patients experienced 70% lower readmissions over 30 days compared to usual care inside the hospital, with a 38% reduction in care costs. Home patients also spent half as much time sedentary than hospital patients, and two-thirds less time lying down. An observational study published in the journal Nature used Biofourmis’ solution to remotely monitor and evaluate 34 patients with COVID-19 (https://www.nature.com/articles/s41598-021-82771-7/tables/1). Clinicians compared the predictive clinical deterioration capability of Biofourmis’ AI to patients who received a standardized, periodic, manual clinical evaluation. Researchers found that the Biofourmis AI’s accuracy rate was 93% with an average prediction time of 21 hours. The control’s accuracy rate was only 64%. Likewise, Biofourmis was 78% accurate at predicting the patients’ length of stay versus 58% accuracy for the control. In addition, a feasibility study presented at the Heart Failure Society of America conference showed the Biofourmis’ medication optimization algorithm led to improved guideline-directed medical therapy (GDMT) adherence for 27 patients with heart failure with reduced ejection fraction. At follow-up, 70% of patients were at or above target doses for certain GDMT drugs compared to only 30% before. Just as importantly, physicians agreed with 95% of the AI’s clinical decision support recommendations for drug and dosage.

Why Us